Navigation Links
Depth of MedImmune's Respiratory Disease Research Program Highlighted at Annual Meeting of the American Thoracic Society
Date:5/15/2008

GAITHERSBURG, Md., May 15 /PRNewswire/ -- MedImmune today announced that researchers will present eight abstracts from its respiratory disease program at the Annual Meeting of the American Thoracic Society, from May 18 to 20, 2008 in Toronto, Canada. Presentations are designed to showcase MedImmune's biologics capabilities.

"MedImmune is committed to finding innovative solutions that may one day help patients struggling with respiratory diseases," said Tony Coyle, vice president, head, autoimmunity inflammation and respiratory disease research. "We are pleased to present a plethora of promising data that could potentially address diseases such as asthma and chronic obstructive pulmonary disease."

MedImmune research scheduled to be presented includes:

-- Regulation of Lung Inflammation in Animal Models (Poster Session:

IL-33, the Ligand for T1/ST2, Induces Airway Hyperresponsiveness Via a

Mast Cell but Not T Cell Dependent Mechanism, publication page A63)

- Sunday, May 18 from 8:15 a.m.- 4:15 p.m., Metro Toronto Convention

Centre, Area E.

-- Viral Infection and Wheezing (Poster Session: Evidence for T-Lymphocyte

Independent Antibody Responses in Primary RSV Infection, publication

page A190)-Sunday, May 18 from 8:15 a.m. - 4:15 p.m., Metro Toronto

Convention Centre, Area A.

-- Chitins: Flying High (Symposium: Hyperresponsiveness and Inflammation

in a Murine Model of Asthma, publication page A501)- Monday, May 19 at

2:45 p.m., Ontario, Fairmont Royal York Hotel.

-- New Insights and Developing Controversies in Clinical Asthma (Poster

Session: Safety Profile, Pharmacokinetics and Biologic Activity of a

Single IV Dose of the Anti IL-5 Receptor Alpha Antibody MEDI-563 in

Patients with Mild Asthma, publication page A569)-Tuesday, May 20 from

8:15 a.m.- 11:00 a.m., Metro Toronto Convention Centre, Room 205A.

-- Eosinophils, Mast Cells and Neutrophils as Modulators of Immunity and

Injury

-- Poster Session: In Vitro Characterization of MEDI-563, a Humanized

Anti-IL-5Ralpha Monoclonal Antibody in Phase1 Clinical Trial,

publication page A602

-- Poster Session: MEDI-563, a Humanized Anti-Human IL-5R alpha Antibody

Binds to Lung Tissue Eosinophils in Asthmatic Patients, publication

page A602

-- Poster Session: A Monoclonal Anti-IL-5 Receptor (IL-5R) alpha

Antibody with Enhanced ADCC Selectively and Efficaciously Depletes

Tissue Eosinophils in IL-5 Transgenic Mice, publication page A603

The preceding presentations will occur on Tuesday, May 20 from 8:15 a.m. - 4:15 p.m., Metro Toronto Convention Centre, Area B.

-- Monocytes and Macrophages in Inflammation, Immunity and Injury (Poster

Session: Role for Alveolar Macrophages in Limiting Primary RSV

Immunopathology, publication page A623) - Tuesday, May 20 from 8:15

a.m. - 4:15 p.m., Metro Toronto Convention Centre, Area B.

About MedImmune

MedImmune is wholly owned by AstraZeneca plc (LSE: AZN.L, NYSE: AZN) and is the worldwide biologics business for the AstraZeneca Group. The company has approximately 3,000 employees worldwide and is headquartered in Gaithersburg, Maryland. MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on infection, oncology, respiratory disease and inflammation, cardiovascular/gastrointestinal disease and neuroscience. For more information, visit MedImmune's website at http://www.medimmune.com.


'/>"/>
SOURCE MedImmune
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Respiratory/Pulmonary Indexes
2. Isis Pharmaceuticals and Thomas, McNerney & Partners Announce That the Newly Formed Altair Therapeutics Will Develop Antisense Drugs for Respiratory Conditions
3. PARI Respiratorys LC PLUS & PRONEB Ultra Deliver Dey, L.P.s New COPD Therapy; Perforomist Launched Yesterday
4. Adams Respiratory Therapeutics and Lipocine Enter into License and Collaboration Agreement
5. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at Digestive Disease Week 2008
6. Retired Supreme Court Justice Sandra Day OConnor and Former House Speaker Newt Gingrich Address Senate Special Committee on Aging, Calling for Urgent Action Against Alzheimers Disease
7. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
8. Vermillions Roundtable Teleconference Highlights Peripheral Artery Disease Diagnostic Program; Features Commentary from Vascular Medicine Expert
9. Novel Approach to Treat Alzheimers and Other Diseases Offered by Targeting Cell Membrane RAFTS
10. Liver Diseases: A Huge European Health Burden, But Some Trends are Positive
11. Sirion Therapeutics Preclinical Studies: Two New Potential Advances in Treatment of Retinal Diseases to be Presented at ARVO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... ... December 06, 2016 , ... Clinical ... it has acquired the assets of Theorem Clinical Research - Clinical Supplies ... clinical trial drug packaging, labeling, storage, reconciliation, and distribution for pharmaceutical trials ...
(Date:12/6/2016)... 6, 2016  SRI International has been awarded ... the National Institutes of Health,s National Institute of ... AIDS (NIAID-DAIDS) to support the manufacturing and characterization ... agents. Under the seven-year contract, SRI will provide ... for candidate HIV-prevention products that emerge from investigator-initiated ...
(Date:12/5/2016)... 5, 2016 Axovant Sciences Ltd. (NYSE: ... on the treatment of dementia, today announced that data ... of Alzheimer,s disease will be presented at the 2016 ... December 9, 2016 in San Diego ... both simple and complex measures of activities of daily ...
(Date:12/5/2016)... ... December 05, 2016 , ... In anticipation of AxioMed’s exclusive ... production, company President, Jake Lubinski will be traveling to Germany on December 6th. ... Cologne and Karlsruhe to discuss the benefits of a viscoelastic total disc replacement. ...
Breaking Biology Technology:
(Date:12/6/2016)... 2016  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ... of €500.0 million principal amount of its 1.414% senior unsecured ... 2.425% senior unsecured notes due 2026. The ... 2016, subject to the satisfaction of customary closing conditions.  The ... The Company intends to use the net ...
(Date:12/6/2016)... , Dec. 6, 2016 Valencell , the ... it has seen a third consecutive year of triple ... technology in 2016 with a 360 percent increase in ... This increase was driven by sales of its wrist ... interest in its technology for hearables for fitness and ...
(Date:12/6/2016)... , Dec. 6, 2016 Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... announced today a five (5) year funding commitment ... to expand the rehabilitation and reentry support to ... History Established in 2004, the Prison Entrepreneurship Program ...
Breaking Biology News(10 mins):